The first two authors contributed equally.
Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using μPET/CT†
Article first published online: 16 DEC 2010
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 10, pages 2058–2064, October 2011
How to Cite
Hindryckx, P., Staelens, S., Devisscher, L., Deleye, S., De Vos, F., Delrue, L., Peeters, H., Laukens, D. and De Vos, M. (2011), Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using μPET/CT. Inflamm Bowel Dis, 17: 2058–2064. doi: 10.1002/ibd.21578
Supported by a grant from the Fund for Scientific Research (Aspirant mandaat-FWO Vlaanderen to Pieter Hindryckx) by Ghent University, by the Institute for BroadBand Technology and imaging (IBBT), and by the BOF fund of Antwerp University. There are no financial disclosures to a company related to the submitted article.
- Issue published online: 11 SEP 2011
- Article first published online: 16 DEC 2010
- Manuscript Accepted: 18 OCT 2010
- Manuscript Received: 10 OCT 2010
- small animal molecular imaging;
- experimental colitis;
This study investigates whether deoxy-2-[18F]fluoro-d-glucose (FDG) micro-positron emission tomography (μPET)/computed tomography (CT) can serve as a tool for monitoring of the commonly used dextran sodium sulfate (DSS)-induced murine model of inflammatory bowel disease (IBD).
DSS-colitis was induced in Sv129 mice. In a first experiment, four animals were serially scanned with CT and FDG-μPET on days 0, 3, 7, 11, and 14. The ratio of the mean voxel count of the PET images in the colon and the brain was compared with the histological inflammation score and the colonic myeloperoxidase levels. A second experiment was performed to investigate whether FDG-μPET was able to detect differences in inflammation between two DSS-treated groups, one receiving placebo (n = 4) and one receiving dimethyloxalylglycine (DMOG) (n = 4), a compound that protects against DSS-induced colitis.
The progression of the colonic/brain FDG-signal ratio (over days 0–14) agreed with the predicted histological inflammation score, obtained from a parallel DSS-experiment. Moreover, the quantification of normalized colonic FDG-activity at the final timepoint (day 14) showed an excellent correlation with both the MPO levels (Spearman's rho = 1) and the histological inflammation score (Spearman's rho = 0.949) of the scanned mice. The protective action of DMOG in DSS colitis was clearly demonstrated with FDG-μPET/CT (normalized colonic FDG-activity DMOG versus placebo: P < 0.05).
FDG-μPET-CT is a feasible and reliable noninvasive method to monitor murine DSS-induced colitis. The implementation of this technique in this widely used IBD model opens a new window for pathophysiological research and high-throughput screening of potential therapeutic compounds in preclinical IBD research. (Inflamm Bowel Dis 2010;)